http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#Head
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#assertion
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#provenance
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#pubinfo
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#assertion
http://purl.obolibrary.org/obo/DOID_2841
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2841
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01136
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association
http://www.w3.org/2000/01/rdf-schema#label
"Carvedilol tablets are contraindicated in the following conditions: Bronchial asthma or related bronchospastic conditions. Deaths from status asthmaticus have been reported following single doses of carvedilol tablets. Second- or third-degree AV block Sick sinus syndrome Severe bradycardia (unless a permanent pacemaker is in place) Patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating carvedilol tablets. Patients with severe hepatic impairment Patients with a history of a serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol. Bronchial asthma or related bronchospastic conditions ( ) 4 Second- or third-degree AV block ( ) 4 Sick sinus syndrome ( ) 4 Severe bradycardia (unless permanent pacemaker in place) ( ) 4 Patients in cardiogenic shock or decompensated heart failure requiring the use of IV inotropic therapy. ( ) 4 Severe hepatic impairment ( , ) 2.4 4 History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol. ( ) 4"
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB01136
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#provenance
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#pubinfo
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#sig
http://purl.org/nanopub/x/hasSignature
L5cZAai1q2+VY2pCsUJy3qKqC1hV/0rqAcQrwTIcZba6X8vE3eoP0EyneS/uEpo67OEgxDc2+8bC/aXD7gjHqO0aCObpYt1PgL9B1m1MVU/RK2syb/BuaOZch049NdwzBJDTrAeyiwK9kDwJ/DvdB3cLQHa+DlcPyhKE8CKayCo=
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw
http://purl.org/dc/terms/created
2021-08-23T18:53:47.046+02:00
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY